The Role of Aspirin in the Prevention of Thrombotic Complications of Thalidomide and Anthracycline-Based Chemotherapy for Multiple Myeloma

This publication has 18 references indexed in Scilit:

• A Phase II Trial of Doxil, Vincristine and Reduced Schedule Dexamethasone (DVd) for Patients with Relapsed or Refractory Multiple Myeloma.
  Blood, 2004
• Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
  British Journal of Haematology, 2004
• Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma
  British Journal of Haematology, 2003
• Cancer and Thrombosis: Mechanisms and Treatment
  Journal of Thrombosis and Thrombolysis, 2003
• Cancer-Related Deep Venous Thrombosis: Clinical Importance, Treatment Challenges, and Management Strategies
  Seminars in Thrombosis and Hemostasis, 2003
• Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment
  Journal of Thrombosis and Haemostasis, 2003
• A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced‐dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients
  Cancer, 2002
• Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy
  Blood, 2002
• Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications
  Blood Coagulation & Fibrinolysis, 2002
• Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
  Blood, 2000